ANAGIN
Indianapolis, IN · Founded 2013 · CIK 0001679399 · Biotech · Private
Neuropsychiatric therapeutics targeting fear and pain disorders
anagin.com →- Grants
- $8.9M
- 9 awards
- Sector median: 1
- Raised
- $2.3M
- 2 Form D · Jun 2018
- 99 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Novel treatment of posttraumatic stress disorder | $343,957 | |
| Federal grant | Department of Health and Human Services · Phase I · nNOS-PSD95 inhibitors as novel treatments for TBI | $267,381 | |
| Private capital raised | Form D · SEC | $950,000 | |
| Federal grant | Department of Health and Human Services · Phase I · High throughput screen to identify small molecule analgesics targeting nNOS-NOS1AP protein-protein interactions | $367,687 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel treatment of posttraumatic stress disorder | $1,373,142 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel treatment of posttraumatic stress disorder | $1,619,914 | |
| Private capital raised | Form D · SEC | $1,308,688 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of novel small molecule analgesics modulating the nNOS-NOS1AP protein-protein interaction | $1,498,044 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of novel small molecule analgesics modulating the nNOS-NOS1AP protein-protein interaction | $1,103,900 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of novel small molecule analgesics modulating the nNOS-NOS1AP protein-protein interaction | $286,072 | |
| Federal grant | Department of Health and Human Services · Phase II · Discovery of PSD95 protein-protein interaction inhibitors as novel non-opioid analgesics | $1,997,154 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2544 | Rare Air Health, Inc. | — | $4.7M |
| 2545 | Neela Therapeutics, Inc. | — | $12M |
| 2546 | Regenerate, Inc. | — | $2.3M |
| 2547 | ANAGIN | — | $2.3M |
| 2548 | Amplo Biotechnology, Inc. | — | $2.2M |
| 2549 | Mira Dx, Inc. | — | $2.1M |
| 2550 | CellVax Therapeutics, Inc. | — | $2.1M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Nora DohertyDirector
- Frank FrenchDirector
- Jaswant GiddaDirector · Executive Officer
- Yvonne LaiExecutive Officer
- James SchulzExecutive Officer
- Anantha ShekharDirector
- Derek SmallDirector
Patents
- Salicylamides And Methods Of Use Thereofapplication
- Salicylamides And Methods Of Use Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.